Esteve-Pastor MA, Rivera-Caravaca JM, Shantsila A, Roldan V, Lip GYH, Marin F. Assessing bleeding risk in atrial brillation patients: comparing a bleeding risk score based only on modi able bleeding risk factors against the HAS-BLED Score. The AMADEUS Trial. Thromb Haemost. 2017;117(12):2261-2266. 81. Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G. Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(suppl 2):e44S-e88S. 82. Fang MC, Chang Y, Hylek EM, et al. Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial brillation. Ann Intern Med. 2004;141(10):745-752. 83. Hylek EM, Skates SJ, Sheehan MA, Singer DE. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial brillation. N Engl J Med. 1996;335(8):540-546. 84. Singer DE, Fang MC, Go AS. The international normalized ratio range of 2.0 to 3.0 remains appropriate for atrial brillation. Arch Intern Med. 2009;169(21):2032; author reply 2033. 85. Walker AM, Bennett D. Epidemiology and outcomes in patients with atrial brillation in the United States. Heart Rhythm. 2008;5(10):1365-1372. 86. Witt DM, Delate T, Hylek EM, et al. Effect of warfarin on intracranial hemorrhage incidence and fatal outcomes. Thrombosis Res. 2013;132(6):770-775. 87. Clarkesmith DE, Pattison HM, Lip GY, Lane DA. Educational intervention improves anticoagulation control in atrial brillation patients: the TREAT randomised trial. PloS One. 2013;8(9):e74037. 88. Levi M, de Peuter OR, Kamphuisen PW. Management strategies for optimal control of anticoagulation in patients with atrial brillation. Semin Thromb Hemost. 2009;35(6):560-567. 1190 Evidence-Based Medicine [ 1 5 4 # 5 C H E S T N O V E M B E R 2 0 1 8 ] 89. Matchar DB, Jacobson A, Dolor R, et al. 